Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2007, p. 2987-2996, Vol. 27, No. 8
0270-7306/07/$08.00+0 doi:10.1128/MCB.01685-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Ben May Department for Cancer Research, The University of Chicago, 924 E. 57th Street, Chicago, Illinois 60637
Received 8 September 2006/ Returned for modification 27 December 2006/ Accepted 3 February 2007
|
|
|---|
|
|
|---|
The Drosophila developing eye is a well-established system to study the coordination between cell cycle regulation and differentiation. The adult Drosophila eye is derived from the so-called eye imaginal discs, which proliferate and differentiate during the larval and pupal stages. Photoreceptor differentiation is initiated within a region referred to as the morphogenetic furrow (MF), which is marked by an indentation in the third larval eye disc. The MF progresses from the posterior part of the eye disc toward the anterior end. Cells in the anterior divide asynchronously, whereas cells in the MF are arrested at G1 and initiate photoreceptor differentiation by forming regularly spaced preclusters. These preclusters will eventually develop into ommatidia, which are the units of the fly compound eye. Posterior to the MF, cells that are not in the clusters undergo a single round of synchronous division, the second mitotic wave, before they exit from the cell cycle (32). In the developing eye, cell cycle exit of the differentiating photoreceptor neurons is controlled by the redundant function of RBF and Dacapo (Dap) (13). Dap is expressed in and just posterior to the MF, where photoreceptor cell differentiation initiates (8, 22). Studies of the cis-regulatory elements that regulate Dap expression identified many independent enhancers, including an eye enhancer, Dap-HB (23, 24).
There are eight photoreceptor cells in each ommatidium, referred to as R1 to R8. During photoreceptor cell differentiation, R8 is determined first, followed by R2 and R5. Specification of the R8 photoreceptor cell requires the proneural genes Atonal (Ato) and Daughterless (Da) (4, 18). Ato and Da are basic helix-loop-helix (bHLH) transcription factors that function together as a heterodimer. Ato is initially expressed at the anterior edge of the MF and becomes progressively refined to clusters of decreasing cell numbers. Immediately before R8 specification, Ato is detected in clusters of two to three cells, which are referred to as "R8 equivalence groups" (9, 18). Later, Ato is maintained only in the R8 photoreceptors while Pointed (Pnt), an Ets family transcription factor regulated by epidermal growth factor receptor (EGFR) signaling, is required for the differentiation and cell cycle arrest of R2 and R5 photoreceptors (34). In addition, EGFR signaling is also required for the recruitment of all subsequent photoreceptors (10).
In this study, we investigated the regulation of Dap expression during cell type specification. We show that a Dap eye disc enhancer (Dap-HB) (23) is active specifically in the R2 and R5 precursors in the developing eye and surprisingly also in the newly recruited leg disc femoral sense organ precursors (SOPs). We demonstrate that Dap-HB enhancer activity in these two cell types is regulated by Ato, Da, and Pnt through the E-box and Pnt binding sites, respectively. Removal of either Ato-Da or Pnt blocks Dap expression in vivo. Similarly, mutations of either the E-box or Pnt binding site significantly decreased Dap-HB enhancer activity. As Ato-Da and EGFR signaling has been shown or implicated in both leg disc femoral SOP recruitment and R2 and R5 specification (18, 34-36), these results indicate that the combination of differentiation factors directly regulates Dap expression while simultaneously functioning in cell fate specification. This is potentially a general mechanism by which dynamic expression of a cdk inhibitor is controlled and coordinated with cell fate specification during normal development.
|
|
|---|
19 (27). The following antibodies were used: anti-Dap (7), anti-PntP1 (1), anti-Ato (19), and anti-Bar (16). Anti-ß-galactosidase (mAb40-1a), Elav, and Rough (ro-62C2A8) were obtained from the Developmental Studies Hybridoma Bank. The genotypes used in this study were (i) GMRGal4/+; UAS-Ato UAS-Da/+, (ii) GMRGal4/+; UAS-Ato UAS-Da/Dap-HB-LacZ, (iii) GMRGal4/UAS-Yan; UAS-Ato UAS-Da/Dap-HB-LacZ, (iv) GMRGal4/UAS-Da; UAS-Ato UAS-PntP1/Dap-HB-LacZ, (v) GMRGal4/+; UAS-Ato UAS-Da/Dap-HB mut1-2-GFP, (vi) Df(2L)da10 FRT40A/UbiGFP FRT40A, (vii) Df(2L)da10 FRT40A/UbiGFP FRT40A; Dap-HB-lacZ/+, (viii) Df(2L)da10 Su(H)
47 FRT40A/UbiGFP FRT40A, (ix) Df(2L)da10 Su(H)
47 FRT40A/UbiGFP FRT40A; Dap-HB-lacZ/+, (x) hsFLP; FRT82B, ato3/FRT82B Ubi-GFP RpS3, (xi) hsFLP; Dap-HB-GFP/+; FRT82B, ato3/FRT82B, Arm-lacZ (cytoplasmic), and (xii) hspFLP; Dap-HB-GFP/+; FRT82B, pnt5484
19/FRT82B, Arm-lacZ (cytoplasmic). BrdU incorporation, immunohistochemistry, and in situ hybridization. Eye discs were dissected, incubated with bromodeoxyuridine (BrdU; final concentration, 75 µg/ml) at room temperature for 60 min, washed with phosphate-buffered saline (PBS), and fixed with 4% paraformaldehyde in PBS, followed by postfixing with 4% paraformaldehyde in PBS-0.6% Tween 20. The discs were washed with DNase I buffer, followed by incubation with DNase I (100 U/500 µl) for 1 h. Mouse anti-BrdU antibody (Becton Dickinson) was used at a 1:50 dilution. Immunohistochemistry and in situ hybridization were performed essentially as previously described (11).
Gel shift assay and generation of transgenic reporter lines. His6-tagged Da (amino acids 347 to 710) and Ato (amino acids 7 to 312) were expressed in bacteria, purified, and renatured together. Gel shift assays were carried out as previously described (12), except that oligonucleotides with mutated E-box binding sites were also labeled as probes. The sequences of the WT (wild-type) and Mut (mutant) probes are as follows: WT1, TCAAAGCTGACTGCAGCTGTTTCAGCTCCTCAT; Mut1, TCAAAGCTGACTGTAAATGTTTCAGCTCCTCAT; WT2, CTATAAATGCCAACAGCTGTGACTCCGCTTTGT; Mut2, CTATAAATGCCAATAAATGTGACTCCGCTTTGT; WT3, ACCGGAAATGCAGCAGCTGACTTTGATTTGGCA; Mut3, ACCGGAAATGCAGTAAATGACTTTGATTTGGCA; E-CG, GCCGTCCACGTGCCACAATCTGGGAA; Mut-CG, GCCGTCTAAATGCCACAATCTGGGAA. The WT and mutant E-box sites are underlined. A PhosphorImager from Molecular Dynamics was used to scan the image, and ImageQuant was used to quantify the intensities of specific gel shift bands. Gel shift assays of Ato-Da with Pnt were carried out with proteins derived by in vitro transcription and translation with a kit from Promega.
The same mutations in the E-box binding sites shown here were introduced into the Dap-HB enhancer by PCR to generate specific E-box-mutated Dap-HB enhancers. The WT and mutated Dap-HB enhancers were sequenced and cloned into the pHStinger vector (2) to generate the new Dap-HB transgenic lines. At least two independent transgenic lines were examined for each Dap-HB construct, and no significant variations in expression were observed.
|
|
|---|
![]() View larger version (69K): [in a new window] |
FIG. 1. The Dap-HB enhancer is active in the R2 and R5 precursors of the developing eye and contains multiple E-box binding motifs that are regulated by Atonal and Daughterless. The level of Dap-HB-GFP reporter expression, as determined by in situ hybridization, is shown in panel A, and the level of GFP is shown in panel B. The GFP observed in the posterior part of the eye disc was due to the stability of the GFP reporter protein. (C) Staining with anti-Elav antibody showed that two cells per ommatidial cluster express GFP driven by Dap-HB. (D to F) Dap-HB drives reporter expression in R2 and R5 precursor cells. The Dap-HB-GFP reporter was expressed in cells (R2 and R5) that were labeled by the anti-Rough antibody (arrowheads in panels D to F). The anti-Rough antibody also stained additional cells (R3 and R4) in the posterior that did not have GFP expression. Rough was reported to be expressed initially in the R2 and R5 cells and later in the R2, R3, R4, and R5 cells posterior to the furrow (9, 20). (G) Gel shift assay showing that the Atonal-Daughterless heterodimer bound strongly and specifically to the CAGC/GTG type of E-box sites in the Dap-HB enhancer. WT1 to WT3 (lanes 1, 3, and 7) and Mut1 to Mut3 (lanes 2, 4, and 8) indicate probes with WT or mutated CAGC/GTG type of E-box binding sites, respectively. E-CG (lane 5) and Mut-CG (lane 6) indicate probes with WT and mutated E-box binding sites that are different from consensus Ato-Da binding sites. The same amounts of Ato-Da protein were added for the gel shift experiment. An arrow points to the Ato-Da-DNA complex. The sequences of the WT and E-box-mutated probes are shown in Materials and Methods. (H to K) Ectopic expression of Atonal and Daughterless in the posterior of the developing eye with the GMR-GAL4 driver increased Dap protein levels (H and I), as well as Dap-HB enhancer activity (J and K). The levels of Dap protein in WT (H) or GMR-Gal4 UASAto-Da (I) eye discs were detected by anti-Dap antibody staining. Activity of the Dap eye disc enhancer, Dap-HB, was determined by anti-ß-galactosidase staining, which is shown in red (J and K). WT and Ato-Da indicate eye discs from Dap-HB/+ and GMR-Gal4/+; Dap-HB/UASAto UASDa larvae, respectively.
|
Ato and Da are sufficient to activate Dap expression in the developing eye. In the developing Drosophila eye, Ato is highly expressed at the anterior edge of the furrow and becomes refined to clusters of decreasing numbers of cells. Before Ato is restricted to the future R8 cells, it is expressed in the two- to three-cell clusters of the R8 equivalence group that are the R8 and R2 and R5 precursors (9, 18). The expression pattern of Ato is consistent with the idea that the Dap-HB enhancer is regulated by the Ato and Da proteins. Therefore, the effects of ectopically activating Ato-Da in the developing eye were characterized with the UAS-Gal4 system (3) to determine if Ato and Da are sufficient to increase the endogenous Dap protein level and Dap-HB enhancer activity.
Dap is expressed in and just posterior to the MF in the developing eye (7, 23). Ectopic expression of Ato and Da in the posterior of the developing eye disc with the GMR-Gal4 driver led to significant accumulation of Dap protein in the posterior (Fig. 1H and I). In addition, ectopic expression of Ato and Da in the posterior region of the eye disc also strongly induced ectopic Dap-HB enhancer activity (Fig. 1J and K). Interestingly, strong upregulation of Dap-HB enhancer activity was observed in the posterior close to the MF but not in the far posterior (Fig. 1K, indicated by an arrow), even though Ato and Da were expressed throughout the posterior of the eye disc. These observations suggest that while ectopic Ato-Da expression is sufficient to activate the Dap-HB enhancer in some eye disc cells, additional factors are also likely involved in Ato-Da-mediated activation of Dap-HB.
Requirements of Da and Ato for Dap expression in the developing eye. Da is a general-class bHLH protein that can form complexes with different cell type-restricted bHLH proteins, including Ato (25). To determine if Da regulates Dap in vivo, the effect of removing Da on the expression of Dap was studied by generating clones of da mutant cells in a da heterozygous background. This technique generates somatic clones of homozygous mutant cells from heterozygous precursors, resulting in adjacent populations of WT and mutant cells that can be easily identified (33). As shown in Fig. 2A to C, da mutant cells are identified by the absence of GFP, and the level of Dap protein was significantly decreased in da mutant clones in the eye disc (n = >10). These results showed that Da is required for the endogenous levels of Dap in the developing eye disc. To further determine if Da regulates Dap at the level of transcription, the effect of removing Da on the activity of the Dap eye disc enhancer Dap-HB was determined. As shown in Fig. 2G to I, Dap-HB enhancer activity was completely blocked in da mutant clones, indicating that Da is required for the transcriptional activation of Dap in the eye disc. Therefore, we conclude that the general-class bHLH protein Da is required for the expression of Dap in the developing eye.
![]() View larger version (70K): [in a new window] |
FIG. 2. Daughterless and Ato are required for endogenous Dap expression in the developing eye. (A to F) The level of Dap protein in da or ato mutant clones was determined by staining with anti-Dap antibody. Decreased Dap protein levels (red staining in panels B, C, E, and F) were observed in the da single-mutant clones (A to C), as well as in the ato single-mutant clones (D to F). These mutant clones are identified by lack of GFP. (G to L) Daughterless and Ato are required for Dap-HB enhancer activity. The Dap-HB-lacZ reporter was used in panels G to I. The da single-mutant clone was identified by lack of GFP. No Dap-HB-lacZ reporter expression (red in panels H and I) was observed in the da mutant clones. The Dap-HB-GFP reporter was used in panels J to L. ato mutant clones are identified by the lack of cytoplasmic ß-galactosidase staining (red in panels J and L), and no Dap-HB-GFP reporter (green in panels K and L) was detected in the ato mutant clones.
|
Da and Ato regulate the Dap-HB enhancer directly through the E-box binding sites. Our observation that removing Da and Ato blocks Dap-HB enhancer activity in the developing eye can be explained either by a direct requirement of Ato and Da for Dap-HB enhancer activity or by an indirect requirement of Da and Ato for the initiation of R2 and R5 photoreceptor cell differentiation. To determine if Ato and Da regulate Dap-HB enhancer activity directly, the effects of mutating the observed E-box binding sites on Dap-HB enhancer activity were examined in the developing eye. As shown in Fig. 3A to C, mutation of E-box binding sites 1 and 2 completely blocked Dap-HB enhancer activity while mutation of E-box binding site 3 also significantly decreased Dap-HB enhancer activity. These results demonstrate that the conserved E-box binding sites are required for Dap-HB enhancer activity in the developing eye disc.
![]() View larger version (42K): [in a new window] |
FIG. 3. Dap-HB enhancer activity requires both the E-box binding sites and a Pnt binding site near E-box binding site 3. (A to E) Effect of mutating the E-box binding sites or the putative Pnt binding site on Dap-HB enhancer activity. The levels of GFP reporter protein from eye discs with WT or mutated Dap-HB enhancers are shown. mE1-2, mE3, mT1, and mT2 indicate Dap-HB enhancers with specific E-box or Pnt binding sites mutated as indicated in panel I. (F to H) Overexpression of Ato-Da in the posterior of the eye disc failed to induce the Dap-HB enhancer with mutated E-box binding sites 1 and 2. The level of Ato is shown by immunostaining (red in panels F and H), and the activity of the Dap-HB enhancer with mutated E-box sites is shown in green (G and H). (I) Diagram of different transgenic Dap-HB enhancers. Filled circles represent E-box binding sites, and filled squares indicate putative Pnt binding sites. The symbol x represents Dap-HB enhancers with mutations in the indicated binding sites.
|
The Dap-HB enhancer contains a Pnt binding site adjacent to an E-box binding site. EGFR signaling has been shown to be required for the cell cycle arrest and differentiation of R2 and R5 cells (34). Our finding that the Dap-HB enhancer is expressed specifically in R2 and R5 precursor cells prompted us to examine if the Dap-HB enhancer is also regulated by Pnt, a transcription factor regulated by EGFR signaling. Examination of the Dap-HB enhancer revealed two putative Pnt binding sites (Fig. 4A, T1 and T2). Gel shift assays were carried out to determine if either the T1 or T2 site can bind to Pnt-P1 protein in vitro. As shown in Fig. 4B, the WT but not mutant T2 site could compete for binding of the Pnt protein (lanes 4 to 6) while neither the WT nor the mutant T1 site could compete for binding of the Pnt protein. These observations suggest that only T2 is an actual Pnt binding site.
![]() View larger version (60K): [in a new window] |
FIG. 4. Ato-Da and PntP1 can bind to the Dap-HB enhancer simultaneously. (A) Diagram of Dap-HB enhancer and nucleotide sequences of the probe used. The sequences of the Pnt binding site (T2) and the E-box motif (E3) are shown in capital letters. (B) Gel shift experiments showing that Pnt protein binds specifically to the T2 site but not the T1 site. In vitro-translated Ato-Da and PntP1 bound to the probe with both T2 and E3 binding sites (lanes 1 and 4), and this binding was competed away specifically by WT E3 and T2 oligonucleotides (lanes 2 and 5) but not by mutated E3 and T2 oligonucleotides (lanes 3 and 6). In contrast, neither the WT nor the mutated T1 oligonucleotide was able to compete for PntP1 binding (lanes 7 to 9). (C) Gel shift assay showing that Ato-Da and Pnt can bind simultaneously to the probe with both T2 and E3 binding sites. A slower-migrating complex was observed when in vitro-translated Ato-Da and PntP1 were mixed in the gel shift assay (lanes 10 to 12). This slower-migrating complex was competed away specifically by an oligonucleotide containing either the T2 or the E3 binding site (lanes 12 to 15). Binding was significantly diminished by anti-Ato (lane 16) or anti-PntP1 (lane 18) antibodies. Con1 and Con2 indicate equal amounts of control sera for specificity of antibody binding to Ato and PntP1, respectively.
|
Dap-HB enhancer activity also requires Pnt. Both Pnt-P1 and Pnt-P2 were shown to contribute to both the G1 arrest and differentiation of the R2 and R5 photoreceptors (34). Previous results indicated that Dap protein levels are reduced but not eliminated in pnt mutant clones (13). As there are potentially multiple enhancers that regulate Dap expression in the developing eye and since Dap-HB is the one that drives expression specifically in the R2 and R5 precursors, we were interested in determining whether Pnt is required for Dap-HB enhancer activity. As shown in Fig. 5A to C, no GFP reporter from the Dap-HB enhancer was observed in pntP1 mutant clones (n, = >15). As a few of the R2 and R5 photoreceptors can still differentiate in pntP1 mutant clones (34), our observations suggest that Pnt proteins likely play a direct role in activation of the Dap-HB enhancer rather than affecting Dap-HB enhancer activity indirectly by blocking differentiation. In support of the idea that Pnt proteins are directly required for Dap-HB enhancer activity, mutation of the T2 Pnt binding site in the Dap-HB enhancer greatly reduced enhancer activity (Fig. 3E). In contrast, disruption of the T1 site, which does not bind Pnt in vitro, had no effect on Dap-HB enhancer activity (Fig. 3D).
![]() View larger version (81K): [in a new window] |
FIG. 5. Pointed is required for Dap-HB enhancer activity. (A to C) Pnt is required for Dap-HB enhancer activity. The Dap-HB-GFP reporter (green in panels B and C) was not observed in pntP1 mutant clones (marked by absence of ß-galactosidase, shown in red in panels A and C). (D to K) Effects of expressing Ato, Da, PntP1, and Yan either alone or in different combinations with the GMR-Gal4 driver. Coexpression of Ato and Da led to synergistic activation of the ß-galactosidase reporter driven by the Dap-HB enhancer (D to G). While expression of PntP1 together with Ato-Da had little additional effect (I), expression of Yan, an inhibitor of Pnt, blocks activation of the Dap-HB enhancer by Ato-Da (K).
|
The Dap-HB enhancer is also active in the leg femoral chordotonal organ SOPs. The above results indicate that Dap expression in R2 and R5 precursors is regulated by the differentiation factors that specify the fate of R2 and R5. In addition to R2 and R5 determination, EGFR signaling and Ato were also shown to be involved in leg femoral SOP specification (36). This prompted us to examine if Dap-HB is also expressed in the femoral SOPs of the developing leg disc during SOP specification. As shown in Fig. 6A, the GFP reporter was expressed in a small cluster of cells in the leg disc. As the leg femoral SOPs can be marked by Senseless (26, 36), our observation that the GFP reporter driven by the Dap-HB enhancer coincided with cells that are marked by Senseless (Fig. 6A to C) indicates that Dap-HB is expressed in a subset of femoral SOPs. In addition, GFP expressed from the Dap-HB enhancer also overlaps Ato (Fig. 6D to F), which is expressed in the overlying proneural cluster and in the newly recruited SOPs but not in mature SOPs (35). We conclude that Dap-HB is an enhancer element that drives Dap expression in newly recruited femoral SOPs but not in mature SOPs. Staining with anti-Pnt-P1 antibody showed that the GFP reporter also overlaps a subset of the Pnt-P1-expressing SOPs (Fig. 6G and H), consistent with the idea that the Dap-HB enhancer expression in leg femoral SOPs is coordinately regulated with SOP recruitment by Pnt and Ato-Da transcription factors. To examine further the requirement of Ato-Da and Pnt for Dap-HB expression in the leg SOPs, GFP reporter activity of Dap-HB enhancers harboring different mutations was studied. Mutation of either the E-box binding site E3 or the adjacent Pnt binding site T2 significantly diminished Dap-HB enhancer activity in the leg disc femoral SOPs (Fig. 6I to K). In addition, mutations in the first two E-box binding sites completely abolished Dap-HB enhancer activity in these cells (Fig. 6L). Therefore, the Dap-HB enhancer requires both the E-box binding sites and the Pnt binding site for full enhancer activity in leg disc femoral SOPs.
![]() View larger version (48K): [in a new window] |
FIG. 6. Dap-HB is expressed in leg disc femoral SOPs during their recruitment. (A to H) Expression of Dap-HB-GFP (green) in leg disc femoral SOPs relative to that of Senseless (red in panels B and C), Ato (red in panels E and F), and PntP1 (red in panels G and H) is shown. Arrows point to SOPs with Dap-HB-GFP expression, and arrowheads in panels E and F point to Ato staining in femoral proneural cluster cells (out of this focal plane). (I to L) Dap-HB enhancer activity in femoral SOPs requires both the E-box binding sites and the Pnt binding site. Mutation of either the E3 binding site (J) or the T2 binding site (K) significantly decreased Dap-HB enhancer activity in leg disc femoral SOPs. Mutations of both E1 and E2 binding sites (L) abolished Dap-HB enhancer activity. (M to R) Dap-HB-GFP expression in leg discs corresponded to femoral SOPs that have high levels of Dap protein (M to O) and are cell cycle arrested, as shown by a lack of BrdU incorporation of Dap-HB-GFP-expressing SOPs (arrows in panels P to R). Arrowheads in panels P to R showed intense BrdU incorporation by some of the mature SOPs.
|
|
|
|---|
It is tempting to speculate that the coordinated control of cell differentiation and Dap expression we observed is a general mechanism by which Dap transcription is regulated in different cell types. If this is the case, one might expect Dap to be regulated by multiple distinct regulatory elements corresponding to different cell types even in the same developing tissue. In support of this, Dap-HB was found to be expressed only in R2 and R5 precursors in the developing eye disc and there are likely additional enhancers that drive Dap expression in other cell types. Similarly, dissection of Dap expression in the embryonic epidermis also showed that multiple enhancers were used in the control of Dap expression in different regions of the epidermis (24). While previous studies showed that Dap is regulated by many cis-acting elements and suggested that Dap is under developmental control (23, 24), no clear mechanism was derived from those studies. The present work provides the first in-depth analysis of the expression of Dap in two well-defined models; we show that, in both cases, the transcription of Dap is regulated by both Ato-Da and EGFR signaling, which are also the factors involved in controlling the differentiation of the respective cell types.
It should be pointed out that our results do not exclude the possibility that Ato might activate another bHLH protein that can dimerize with Da and activate Dap-HB expression in conjunction with Pnt in the R2 and R5 precursors. However, given the specific physical interaction between Ato and Pnt (36) and the similar organization of the E-box and Pnt binding sites between the Ato autoregulation enhancer and the Dap-HB enhancer, we favor the idea that Ato-Da activates Dap directly, at least through the E-box 3 site.
Importantly, the ability of bHLH proteins to coordinately induce cell differentiation and cell cycle inhibitor expression appears to be an evolutionarily conserved mechanism. In this study, we showed that the bHLH proteins Ato and Da coordinate Dap expression with photoreceptor cell differentiation and SOP recruitment. Previous studies of myocyte differentiation in mammalian tissue culture systems have shown that the myogenic bHLH proteins coordinately regulate muscle cell differentiation and induction of the cdk inhibitor p21 (14, 15, 28). As large numbers of bHLH proteins have been implicated in the cell fate determination of diverse cell types in both mammals and flies (31), it is possible that these bHLH proteins may also control cell cycle inhibitor expression through a similar mechanism and that the inhibitors of the bHLH proteins such as the Id (inhibitor of differentiation) family of proteins (29) may control cell proliferation, at least in part, by antagonizing the induction of the Cip/Kip family of cdk inhibitors by the bHLH proteins.
While Dap was found to be expressed transiently just before cell cycle exit in diverse cell types (8, 22), analysis of the effect of removing Dap showed that Dap is not always essential for the G1 arrest of those cells. In the developing photoreceptor preclusters, for example, it was shown RBF and Dap function redundantly for the G1 arrest of the precluster cells (13). As the G1 arrest of these cells during cell fate specification is essential for normal development, multiple mechanisms have likely evolved to ensure the cell cycle arrest of these cells before differentiation. Therefore, the induction of Dap during cell fate specification potentially provides a fail-safe mechanism to ensure the G1 arrest of the differentiating cells.
This work is supported by grants from NIH and ACS to W.D. W.D. is a Leukemia and Lymphoma Society scholar.
Published ahead of print on 12 February 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»